Abstract 4724: Novel and selective inhibitors of histone deacetylases (HDAC) 1 and 2 synergize with DNA methyltransferase inhibitor azacitidine in acute myeloid leukemia (AML)

@inproceedings{Min2016Abstract4N,
  title={Abstract 4724: Novel and selective inhibitors of histone deacetylases (HDAC) 1 and 2 synergize with DNA methyltransferase inhibitor azacitidine in acute myeloid leukemia (AML)},
  author={Chengyin Min and Steven Norman Quayle and Pengyu Huang and Jeffrey R Shearstone and S. Shephard Jones and Min Yang},
  year={2016}
}
Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA AML is a heterogeneous group of hematopoietic stem cell disorders characterized by defects in myeloid differentiation and increased proliferation of neoplastic hematopoietic precursor cells. Outcomes for patients with AML remain generally poor, highlighting the need for novel treatment options. Aberrant epigenetic regulation plays an important role in the pathogenesis of AML, and the DNA methyltransferase inhibitor… CONTINUE READING

Similar Papers

Topics from this paper.

Citations

Publications citing this paper.